Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...

The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Six years into espnW Summit NYC, brands increasingly want in on the gathering of institutional women's sports knowledge. In ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE ...

With its 2-star rating, we believe Lilly stock is overvalued compared with our long-term fair value estimate of $650 per ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Washington’s hottest new lobbyist has no experience in Washington but a long friendship with Donald Trump Jr.

IBM is making a major bet on America's tech future. The company announced plans on Monday to invest $150 billion across the ...

The 13-year-old daughter of a Jefferies analyst asked about the effect of GLP-1 oral medications during PepsiCo’s most recent ...

As the tariff wars continue to unfold, the markets are attempting to kick off the week with gains as the latest slew of tech ...